Cisplatin aids survival of high-risk head and neck cancer

Source: www.oncologyreport.com Author: Miriam E. Tucker Adding chemotherapy to radiotherapy improved 10-year survival of resectable head and neck carcinomas among high-risk patients who had microscopically involved resection margins and/or extracapsular spread of disease – but not in high-risk patients who only had tumor in multiple lymph nodes. The findings come from a long-term update and unplanned subset analysis of 410 evaluable patients from the RTOG (Radiation Therapy Oncology Group) 9501 phase III study, which previously showed no overall survival advantage from the addition of cisplatin chemotherapy to radiation. The new data are "good news," according to lead author Dr. Jay Cooper, director of Maimonides Cancer Center in Brooklyn, N.Y. "We now can eradicate some advanced head and neck tumors that we couldn’t before by adding chemotherapy to radiation therapy. At the same time, we can spare other patients who would not do better with the addition of chemotherapy from its side effects," he said at a head and neck cancer symposium sponsored by the American Society for Radiation Therapy. The RTOG 9501 study randomized 459 patients with high-risk, resected head and neck cancers to receive either radiation therapy of 60 Gy in 6 weeks (RT), or identical radiotherapy plus cisplatin at 100 mg/m2 IV on days 1, 22, and 43 (RT+CT). When reported at a median follow-up of 45.9 months, the locoregional control rate was significantly higher in the combined-therapy group than in the group given radiotherapy alone (hazard ratio for locoregional recurrence, 0.61); disease-free survival was significantly longer with [...]

2012-02-03T19:44:50-07:00February, 2012|Oral Cancer News|

Squamous cell subgroups respond differently to treatment

Source: www.medscape.com Author: Nancy A. Melville A long-term follow-up of patients with head and neck squamous cell carcinoma suggests that only certain high-risk subgroups benefit from radiation plus chemotherapy. This information will spare patients who will not benefit from undergoing the additional treatment. According to the study, presented here at the 2012 Multidisciplinary Head and Neck Cancer Symposium, patients with microscopically involved resection margins and/or extracapsular spread of disease had a lower risk for cancer recurrence with radiation plus chemotherapy 10 years later, whereas those with tumors in multiple lymph nodes did not benefit from combination treatment; they fared better with radiation alone. "The clinical implication of these findings is that the high-risk group of patients is not as homogenous a group as we believed it was before the study started," lead author Jay S. Cooper, MD, director of the Maimonides Cancer Center, in Brooklyn, New York, told Medscape Medical News. Dr. Cooper and his colleagues analyzed 10 years of follow-up data from the Radiation Therapy Oncology Group (RTOG) 9501/Intergroup phase 3 trial, which examined 410 patients with high-risk resected head and neck cancers. The patients were considered high risk for cancer recurrence because they had microscopically involved resection margins, extracapsular spread of disease, or multiple lymph node involvement. "The allocation was equally divided [according to treatment regimen] at the beginning of the study; the groups were not intended to be balanced for the different [risk] factors," Dr. Cooper said. "We thought they were all equally important." The treatment regimen [...]

Floor of the mouth cancer requires more aggressive treatment to prevent metastases

Source: www.docguide.com Author: Louise Gagnon More aggressive management of squamous cell carcinoma (SCC) of the floor of the mouth has decreased the number of failures in local, regional, and distant metastases, according to a retrospective chart review presented here at the 2nd World Congress of the International Academy of Oral Oncology (IAOO). In the study, a total of 142 treatment-naïve patients with newly diagnosed floor of mouth cancer received treatment with curative intent from 1994 through 2004 at the Princess Margaret Hospital in Toronto, Ontario. About a third of patients received postoperative radiation, explained lead author Jane Lea, MD, Department of Otolaryngology-Head and Neck Surgery at the University of Toronto/Princess Margaret Hospital. The researches wanted to review outcomes and assess any predictive information of survival in patients, noted Dr. Lea. "We wanted to determine clinical and pathological prognosticators of survival," Dr. Lea told attendees at an oral abstract session on July 9. The primary mode of treatment was surgery, with the majority (91%) of those undergoing surgery undergoing neck dissections, noted Dr. Lea. Overall 5-year survival was 68%, and 5-year cause-specific survival was 80%. Mortality due to floor of mouth disease was 14%, and failures were reported in 24 patients. Researchers compared the outcome of this chart review to previously published reviews on the management of SCC of the floor of mouth and found more aggressive management, characterised by increased rates of neck dissections, in their practice compared with management of the condition in the 1970s and 1980s. The more [...]

Go to Top